TP53 and acute myeloid leukemia: While somatic mutations in the tumor suppressor gene TP53 (8%) and 11q23 rearrangements (4%) are more rare in de novo AML, these alterations tend to be enriched in secondary AML (sAML), which is defined as leukemia that has progressed from an antecedent hematologic disorder or is related to prior therapy with cytotoxic agents or radiation (68, 70).